VIDEO: New data show Stelara safe, induces long-term remission in UC

In a Healio video exclusive, Jan Wehkamp, MD, global strategy leader for gastroenterology at Janssen Pharmaceuticals, reports key data points from the company’s 3-year, phase 3 UNIFI study.
Among ulcerative colitis patients treated with 90 mg subcutaneous Stelara (ustekinumab, Janssen) every 8 weeks or every 12 weeks in the long-term extension study, 56.3% and 54.1%, respectively, achieved symptomatic remission at week 152, with 98% and 94.6% corticosteroid free; corticosteroid-free symptomatic remission rates were 55.1% and 51.2%, respectively.
Researchers noted no major adverse events.
“We

In a Healio video exclusive, Jan Wehkamp, MD, global strategy leader for gastroenterology at Janssen Pharmaceuticals, reports key data points from the company’s 3-year, phase 3 UNIFI study.
Among ulcerative colitis patients treated with 90 mg subcutaneous Stelara (ustekinumab, Janssen) every 8 weeks or every 12 weeks in the long-term extension study, 56.3% and 54.1%, respectively, achieved symptomatic remission at week 152, with 98% and 94.6% corticosteroid free; corticosteroid-free symptomatic remission rates were 55.1% and 51.2%, respectively.
Researchers noted no major adverse events.
“We